MyHealthVerse’s Post

What if I told you we could potentially develop a drug addiction treatment using #LPS? 💊 You read that right! At LPS-BioSciences we can extract and characterize LPS from any #Gram-negative bacterium including #Klebsiella oxytoca, which has been shown to potentially reduce #METH cravings! 👩🔬 A March 2023 study suggests that #LPS can reduce #methamphetamine cravings by modulating microglia, the brain's primary immune cells, highlighting the gut-brain axis's significance in addiction #therapy. 🦠 These findings suggest we can develop novel, non-invasive treatments for substance abuse using LPS, opening new avenues for reducing relapse rates and improving long-term recovery outcomes. 📚 Thanks to the authors of this article: #Gut-derived #bacterial LPS attenuates incubation of methamphetamine craving via modulating microglia for this study. ➡ To learn more about LPS extraction for drug development follow this link: https://lnkd.in/e2GRqnbV

Do ECS Variants Affect Personality and Alcohol Addiction? Emerging evidence highlights the endocannabinoid system's crucial role in brain reward mechanisms and addiction. ➡️ Endocannabinoids that signal through the cannabinoid-1 receptor, encoded by the CNR1 gene, are implicated in the addictive effects of alcohol. ➡️ A longitudinal Swedish study with 2,915 participants indicates that a particular genotype of the CB1 receptor may influence both personality and alcohol consumption. Researchers from the Department of Public Health Sciences, Stockholm University, Sweden note that their findings support the idea that the endocannabinoid system can affect alcohol intake behaviors, especially when interacting with life adversities. ✅ Authors state that “their study supports the notion that the ECS can affect alcohol intake behaviors by interacting with life adversities.” Source: Bornscheuer L, Lundin A, Forsell Y, Lavebratt C, Melas PA. The cannabinoid receptor-1 gene interacts with stressful life events to increase the risk for problematic alcohol use. Sci Rep. 2022 Mar 23;12(1):4963. doi: 10.1038/s41598-022-08980-w. PMID: 35322131; PMCID: PMC8941304.

CURE GABA-A | Did you know? GABAAR are key to how our brains process alcohol. These receptors regulate GABA, the brain’s main calming neurotransmitter, which is why alcohol often makes people feel relaxed. But here’s the interesting part: variations in certain GABAAR subunits, like GABRA2, GABRA4, and GABRD, can make some people more sensitive to alcohol’s effects or increase the risk of developing a dependency. This means our brain chemistry plays a bigger role in alcohol use than we often realize. Research shows that alcohol dependency isn’t just about behavior, it’s deeply tied to biology. By understanding how GABAARs influence alcohol’s effects, scientists are uncovering new ways to address dependency and support recovery. Why Target GABAARs with Gene Therapy? GABAARs sit at the intersection of many neurological and psychiatric conditions. By correcting the underlying dysfunction in specific subunits: Addiction: Could be addressed by rebalancing reward pathways and reducing substance-induced GABAAR hypersensitivity. Epilepsy: Could be managed by restoring inhibitory signaling to prevent hyperexcitability. If you know someone struggling with dependency, please consider donating generously. Your support can help fund critical research and pave the way toward groundbreaking treatments to address the root causes of addiction. Together, we can make a difference. https://lnkd.in/gJiiEFYY #CUREGABAA #AlcoholDependency #BrainScience #SupportResearch #GABAAR #GABA #GABAA #GABRA2 #GABRA4 #GABRD Alcohol and Drug Foundation Alcoholics Anonymous World Services, Inc. Network of Alcohol and other Drugs Agencies (NADA) Alcohol Addiction Treatment Addiction Professionals

Dr. Marc Siegel has recently shared insights on the potential of medications like Ozempic and Wegovy in addressing alcohol abuse. These medications, primarily used for diabetes and obesity, belong to a class known as GLP-1s, or glucagon-like peptide-1 receptor agonists. Dr. Siegel highlights research indicating that GLP-1s may help reduce cravings for addictive substances, including […]

An intriguing study reveals that Semaglutide (commonly known as Ozempic or Wegovy) may reduce opioid overdose by 40% and binging of alcohol by 50%. Beyond their weight loss and antidiabetic benefits, these GLP-1 receptor agonists also offer a significant reduction in opioid overdose and alcohol addictions! Study: https://lnkd.in/e4VAqaUn https://lnkd.in/e7MD8MuQ. https://lnkd.in/g6J-T_jM #semaglutide #opioid overdose #GLP-1 receptor agonists #ozempic #wegovy #weightloss

Kratom addictive? 🍃”with little to no addiction potential demonstrated in pre-clinical studies”🍃 Receptor Selectivity and Therapeutic Potential of Kratom in Substance Use Disorders “These therapeutic uses have been hypothesized to be a result of biased signaling at opioid receptors and the poly-pharmacology of the alkaloids at opioid and adrenergic receptors, with little to no addiction potential demonstrated in pre-clinical studies. Thus, the present review highlights the most recent findings on receptor binding and preclinical evidence to explore the use of kratom and its alkaloids as potentially effective pharmacotherapies for OUD and possible other SUDs.” https://lnkd.in/gCttmzre

Are you searching for a high quality compound. Venkatasai offering Buprenorphine EP Impurities A we have in stock with good quality and compair to market will give the best price. Buprenorphine is a partial opioid agonist used for management of severe pain that is not responsive to alternative treatments. Also used for maintenance treatment of opioid addiction. Buprenorphine is a weak partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist used for the treatment of severe pain It is also commonly used as an alternative to methadone for the treatment of severe opioid addiction Buprenorphine is commercially available as the brand name product Suboxone which is formulated in a 4:1 fixed-dose combination product along with naloxone, a non-selective competitive opioid receptor antagonist. Combination with naloxone is intended to reduce the abuse potential of Suboxone, as naloxone is poorly absorbed by the oral route (and has no effect when taken orally), but would reverse the opioid agonist effects of buprenorphine if injected intravenously Buprenorphine has poor gastrointestinal absorption and is therefore formulated as a sublingual tablet. Buprenorphine has a number of unique pharmacokinetic and pharmacodynamic properties that make it a preferred agent for the treatment of conditions requiring high doses of strong oploids For example, buprenorphine dissociates from opioid receptors very slowly, resulting in a long duration of action and relief from pain or withdrawal symptoms for upwards of 24-36 hours. Use of once daily buprenorphine may benefit individuals who have developed tolerance to other potent opioids and who require larger and more frequent doses. Buprenorphine may also be a preferred agent over methadone (which is also commonly used to treat severe pain and opioid use disorder), as it has less effect on Qte interval prolongation fewer drug interactions, reduced risk of sexual side effects. 17 and an improved safety profile with a lower risk of overdose and respiratory depression * Does anyone have a requirement please contact us below mail id market@venkatasailifesciences.com. #pharamacitical #venkatasai #Buprenorphine #chemistry

A study on patients after opioid #overdose discovered that support from trained peer #recovery specialists was just as effective as that from licensed social workers. Certified peer recovery support specialists offer referrals and up to 90 days of follow-up support, including education on overdose prevention, assistance with treatment barriers, and motivation to stay on track. In contrast, support from social workers usually stops when the patient leaves the emergency room. #opioidusedisorder #harmreduction #emergencymedicine #pharmacists #socialwork #psychotherapy #addiction

Recent article from the The Globe and Mail - Company Exciting developments in the field of mental health: There is a growing number of psychedelics receiving FDA breakthrough status since 2017 for mental disorders. With FDA approval on the horizon for MDMA and expanded human trials for psilocybin, the potential impact on #mentalhealth is substantial. The recent surge in financing for psychedelics developers underscores growing investor confidence in their clinical outcomes. Despite questions around commercial viability, the psychedelic renaissance is gaining momentum, offering hope for millions affected by mental health disorders. For the full article: https://lnkd.in/e-DA288r #PsychedelicRenaissance #MentalHealth #Innovation #Wellbeing #Psilocybin #Research #Wellness

Disulfiram Implant Esperal Esperal implant, aka disulfiram-based implant, recently became the #1 treatment method in an alcohol addiction clinic. Disulfiram is a drug discovered in the 1920s and has been used since 1951 to cure chronic alcoholism due to its ability to increase the immune system’s sensitivity to alcohol. Disulfiram is the drug that prevents the release of the body enzyme that metabolizes alcohol. The inhibition of this enzyme causes severe problems, discomfort, and, in some rare cases, even health hazards to humans. Some people who drink alcohol build up a chemical called acetaldehyde in their bodies, which causes pain and an unpleasant physical reaction. Dehydrogenase, an enzyme in the liver, does not break down or metabolize this substance. Read more: https://lnkd.in/dNxQZxr